JNJ - Johnson & Johnson's RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Priority Review as potential first-in-cla
JNJ - Johnson & Johnson's RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Priority Review as potential first-in-class EGFR- and MET-targeted subcutaneous treatment for advanced head and neck cancer - Click For Release
Story updates
12:35:38 PM UTC
SquawkNews
JNJ Johnson & johnson’s rybrevant faspro™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA priority review as potential first-in-class egfr- and met-targeted subcutaneous treatment for advanced head and neck cancer
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.